Admissions open for Southern Alberta Medical Program
The University of Lethbridge and the University of Calgary are partnering to kickstart a new chapter in Alberta's medical education system.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Organ and tissue donations up in 2024: AHS
An Alberta Health Services sign can be seen in this undated file photo. (File) Alberta is on a streak for increasing organ and tissue donations, with a record-breaking year in 2024. Give Life Alberta, through Alberta Health Services, is the provincial organ and tissue donation program. In 2024, they reported a total of 317 deceased donors. 'The generosity of these people and their loved ones led to 423 organs transplanted in 2024, saving hundreds of lives,' said a release from the program on Tuesday. It's the third year in a row for increased donation rates after 2022 saw 248 donors and 2023 had 273. Give Life Alberta said one organ donor can save up to eight lives, while a tissue donor can 'dramatically improve, or sometimes save, up to 75 lives.' They said that in the province alone, there are more than 500 people waiting for 'life-changing' transplants. Medical director of the program Andreas Kramer said that donations can also 'provide families with some comfort during a time of great loss.' 'The fact that we're able to provide that option for more families is good news,' said Kramer. In the past few years, the province has introduced initiatives for people who are considering donation, including mandatory referrals, specialized care physicians and a program that unites health-care teams in Edmonton and Calgary. More information on deceased organ and tissue donation can be found on their website. Albertans who want to register can go there or to a registry office to inform loved ones about their decision to donate.
Globe and Mail
an hour ago
- Globe and Mail
Novo Nordisk expands lawsuits in U.S. against weight-loss drug compounders
Danish drugmaker Novo Nordisk NVO-N said on Tuesday it has filed 14 new lawsuits in the U.S. against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-loss and diabetes drugs, Wegovy and Ozempic. The new lawsuits target companies producing compounded versions of semaglutide 'under the fake guise of personalization,' Novo said. Novo told Reuters its filing lawsuits against telehealth firms, compounding pharmacies and medical spas, including Prism Aesthetics, Mochi Health and Fella Health. Some of these companies have also been named in Eli Lilly's lawsuits, which accuse them of selling knockoff versions of tirzepatide, the active ingredient in Lilly's weight loss drug Zepbound. However, Novo has not filed a lawsuit against major telehealth firm Hims & Hers HIMS-N, which extended its losses nearly 11 per cent in afternoon trade after reporting weaker-than-expected quarterly revenue. Compounders copy brand-name medicines that are in short supply by combining, mixing or altering drug ingredients to meet demand. These companies were temporarily allowed to produce compounded doses of Novo's obesity and diabetes drugs when the Food and Drug Administration declared them in short supply. When the agency later banned the sale of these copies, Hims and Hers shifted to creating versions of semaglutide in personalized doses not offered by branded manufacturers. Novo's lawsuits allege that telehealth providers violate state corporate practice of medicine laws by improperly influencing doctors' decisions and steering patients toward knockoff compounded 'semaglutide' under the guise of personalized medicine. Novo said these are unapproved knockoffs, often made with illicit foreign active pharmaceutical ingredients (API), and have not been proven safe or effective.
CTV News
an hour ago
- CTV News
Cancer survivor partially completes charity swim
Winnipeg Watch A man who survived cancer twice successfully swam 16 kilometres across Lake Winnipeg Sunday.
